Back to search results

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Abroad (travel likely)RecruitingPHASE2

Conditions

Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • UPMC Hillman Cancer Center - Radiation Oncology, Pittsburgh, Pennsylvania, United States

    Contact: Study coordinator (Samantha Demko, RN) · albesl@upmc.edu · 412-647-9015
    Contact: Study coordinator (Brieana Marino, MS) · rowlesbm@upmc.edu · 412-647-8258
    Contact: Principal Investigator (Christopher T Wilke, MD)
Study leads

  • Christopher T Wilke, MD

    Principal Investigator

    University of Pittsburgh

View source on ClinicalTrials.gov(opens in a new tab)